Journal of Hematology & Oncology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=882300, encodeId=b6d4882300bf, content=投稿三天，编辑拒稿，效率还是很高的😂，推荐转投到 biomarker research。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=Dr H, createdTime=Thu Sep 03 00:33:03 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067227, encodeId=ae76106e22758, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实验楼不同方向课题组在一年内试投过5篇，2篇10天内拒稿，2篇送外审一个月后拒稿，1篇大修后接收。请3-4个审稿人，审稿人看的非常细，专业性很强，有创新性要求，article不容易中，基本要所有审稿人都给积极意见才能有机会修回。一般一审10天，送外审的再加3周，从投稿到返回外审意见1个半月。修回再投同样经历送外审差不多一个月返回意见。(状态会经历new submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，revise，revise submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，accept), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dac42363429, createdName=billljc, createdTime=Fri Nov 05 11:52:37 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187268, encodeId=dc64118e268c2, content=这个杂志在华裔主编的运作下从6分涨到20+ 以前文章质量一般配不上十几分但是看了最近半年的国人发的research article 确实还是可以的。个别文章感觉好过cell research😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Sat Jan 22 19:57:20 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103448, encodeId=875d110344881, content=什么样的图表可以用来发文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103447, encodeId=014e110344ed8, content=整理结果过程中，哪张图和哪张图应该放在一起？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579590, encodeId=03805e95904d, content=目前接受一篇。editor assigned完了是reviewers assigned，然后under review，一个月后审完，修改一周后submit，3天后接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/16/effe1e161c052d399c7711bb91050ff8.jpg, createdBy=232e1969427, createdName=1e158756m99(暂无匿称), createdTime=Sat Nov 09 00:00:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589816, encodeId=8d1158981632, content=editor assigned 一周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e9730982, createdName=guoyuanliu, createdTime=Tue Apr 28 00:00:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187866, encodeId=affb218e86669, content=投稿命中率:5.0 经验分享：，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed1e5279534, createdName=1483da0bm95(暂无昵称), createdTime=Sun Feb 18 01:16:58 CST 2024, time=2024-02-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2172085, encodeId=6b8321e2085ce, content=请问接收肺癌靶向治疗方向的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 12:41:53 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2153449, encodeId=d1e3215344999, content=偏重的研究方向：肿瘤 经验分享：这个杂志太bug了，我们投稿两个半月，中间显示有5个reviewer accepted，最后居然说没有找到reviewer，就把我们拒了。简直太不负责任了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55d38610766, createdName=Forever066, createdTime=Fri Aug 18 19:19:26 CST 2023, time=2023-08-18, status=1, ipAttribution=广东省)]

2020-09-03 Dr H

投稿三天，编辑拒稿，效率还是很高的😂，推荐转投到 biomarker research。

266 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=882300, encodeId=b6d4882300bf, content=投稿三天，编辑拒稿，效率还是很高的😂，推荐转投到 biomarker research。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=Dr H, createdTime=Thu Sep 03 00:33:03 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067227, encodeId=ae76106e22758, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实验楼不同方向课题组在一年内试投过5篇，2篇10天内拒稿，2篇送外审一个月后拒稿，1篇大修后接收。请3-4个审稿人，审稿人看的非常细，专业性很强，有创新性要求，article不容易中，基本要所有审稿人都给积极意见才能有机会修回。一般一审10天，送外审的再加3周，从投稿到返回外审意见1个半月。修回再投同样经历送外审差不多一个月返回意见。(状态会经历new submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，revise，revise submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，accept), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dac42363429, createdName=billljc, createdTime=Fri Nov 05 11:52:37 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187268, encodeId=dc64118e268c2, content=这个杂志在华裔主编的运作下从6分涨到20+ 以前文章质量一般配不上十几分但是看了最近半年的国人发的research article 确实还是可以的。个别文章感觉好过cell research😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Sat Jan 22 19:57:20 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103448, encodeId=875d110344881, content=什么样的图表可以用来发文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103447, encodeId=014e110344ed8, content=整理结果过程中，哪张图和哪张图应该放在一起？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579590, encodeId=03805e95904d, content=目前接受一篇。editor assigned完了是reviewers assigned，然后under review，一个月后审完，修改一周后submit，3天后接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/16/effe1e161c052d399c7711bb91050ff8.jpg, createdBy=232e1969427, createdName=1e158756m99(暂无匿称), createdTime=Sat Nov 09 00:00:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589816, encodeId=8d1158981632, content=editor assigned 一周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e9730982, createdName=guoyuanliu, createdTime=Tue Apr 28 00:00:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187866, encodeId=affb218e86669, content=投稿命中率:5.0 经验分享：，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed1e5279534, createdName=1483da0bm95(暂无昵称), createdTime=Sun Feb 18 01:16:58 CST 2024, time=2024-02-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2172085, encodeId=6b8321e2085ce, content=请问接收肺癌靶向治疗方向的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 12:41:53 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2153449, encodeId=d1e3215344999, content=偏重的研究方向：肿瘤 经验分享：这个杂志太bug了，我们投稿两个半月，中间显示有5个reviewer accepted，最后居然说没有找到reviewer，就把我们拒了。简直太不负责任了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55d38610766, createdName=Forever066, createdTime=Fri Aug 18 19:19:26 CST 2023, time=2023-08-18, status=1, ipAttribution=广东省)]

2021-11-05 billljc

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤
经验分享：实验楼不同方向课题组在一年内试投过5篇，2篇10天内拒稿，2篇送外审一个月后拒稿，1篇大修后接收。请3-4个审稿人，审稿人看的非常细，专业性很强，有创新性要求，article不容易中，基本要所有审稿人都给积极意见才能有机会修回。一般一审10天，送外审的再加3周，从投稿到返回外审意见1个半月。修回再投同样经历送外审差不多一个月返回意见。(状态会经历new submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，revise，revise submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，accept)

149 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=882300, encodeId=b6d4882300bf, content=投稿三天，编辑拒稿，效率还是很高的😂，推荐转投到 biomarker research。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=Dr H, createdTime=Thu Sep 03 00:33:03 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067227, encodeId=ae76106e22758, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实验楼不同方向课题组在一年内试投过5篇，2篇10天内拒稿，2篇送外审一个月后拒稿，1篇大修后接收。请3-4个审稿人，审稿人看的非常细，专业性很强，有创新性要求，article不容易中，基本要所有审稿人都给积极意见才能有机会修回。一般一审10天，送外审的再加3周，从投稿到返回外审意见1个半月。修回再投同样经历送外审差不多一个月返回意见。(状态会经历new submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，revise，revise submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，accept), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dac42363429, createdName=billljc, createdTime=Fri Nov 05 11:52:37 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187268, encodeId=dc64118e268c2, content=这个杂志在华裔主编的运作下从6分涨到20+ 以前文章质量一般配不上十几分但是看了最近半年的国人发的research article 确实还是可以的。个别文章感觉好过cell research😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Sat Jan 22 19:57:20 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103448, encodeId=875d110344881, content=什么样的图表可以用来发文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103447, encodeId=014e110344ed8, content=整理结果过程中，哪张图和哪张图应该放在一起？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579590, encodeId=03805e95904d, content=目前接受一篇。editor assigned完了是reviewers assigned，然后under review，一个月后审完，修改一周后submit，3天后接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/16/effe1e161c052d399c7711bb91050ff8.jpg, createdBy=232e1969427, createdName=1e158756m99(暂无匿称), createdTime=Sat Nov 09 00:00:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589816, encodeId=8d1158981632, content=editor assigned 一周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e9730982, createdName=guoyuanliu, createdTime=Tue Apr 28 00:00:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187866, encodeId=affb218e86669, content=投稿命中率:5.0 经验分享：，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed1e5279534, createdName=1483da0bm95(暂无昵称), createdTime=Sun Feb 18 01:16:58 CST 2024, time=2024-02-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2172085, encodeId=6b8321e2085ce, content=请问接收肺癌靶向治疗方向的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 12:41:53 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2153449, encodeId=d1e3215344999, content=偏重的研究方向：肿瘤 经验分享：这个杂志太bug了，我们投稿两个半月，中间显示有5个reviewer accepted，最后居然说没有找到reviewer，就把我们拒了。简直太不负责任了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55d38610766, createdName=Forever066, createdTime=Fri Aug 18 19:19:26 CST 2023, time=2023-08-18, status=1, ipAttribution=广东省)]

2022-01-22 目标cancer discovery

这个杂志在华裔主编的运作下从6分涨到20+ 以前文章质量一般配不上十几分但是看了最近半年的国人发的research article 确实还是可以的。个别文章感觉好过cell research😂😂

81 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=882300, encodeId=b6d4882300bf, content=投稿三天，编辑拒稿，效率还是很高的😂，推荐转投到 biomarker research。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=Dr H, createdTime=Thu Sep 03 00:33:03 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067227, encodeId=ae76106e22758, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实验楼不同方向课题组在一年内试投过5篇，2篇10天内拒稿，2篇送外审一个月后拒稿，1篇大修后接收。请3-4个审稿人，审稿人看的非常细，专业性很强，有创新性要求，article不容易中，基本要所有审稿人都给积极意见才能有机会修回。一般一审10天，送外审的再加3周，从投稿到返回外审意见1个半月。修回再投同样经历送外审差不多一个月返回意见。(状态会经历new submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，revise，revise submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，accept), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dac42363429, createdName=billljc, createdTime=Fri Nov 05 11:52:37 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187268, encodeId=dc64118e268c2, content=这个杂志在华裔主编的运作下从6分涨到20+ 以前文章质量一般配不上十几分但是看了最近半年的国人发的research article 确实还是可以的。个别文章感觉好过cell research😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Sat Jan 22 19:57:20 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103448, encodeId=875d110344881, content=什么样的图表可以用来发文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103447, encodeId=014e110344ed8, content=整理结果过程中，哪张图和哪张图应该放在一起？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579590, encodeId=03805e95904d, content=目前接受一篇。editor assigned完了是reviewers assigned，然后under review，一个月后审完，修改一周后submit，3天后接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/16/effe1e161c052d399c7711bb91050ff8.jpg, createdBy=232e1969427, createdName=1e158756m99(暂无匿称), createdTime=Sat Nov 09 00:00:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589816, encodeId=8d1158981632, content=editor assigned 一周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e9730982, createdName=guoyuanliu, createdTime=Tue Apr 28 00:00:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187866, encodeId=affb218e86669, content=投稿命中率:5.0 经验分享：，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed1e5279534, createdName=1483da0bm95(暂无昵称), createdTime=Sun Feb 18 01:16:58 CST 2024, time=2024-02-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2172085, encodeId=6b8321e2085ce, content=请问接收肺癌靶向治疗方向的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 12:41:53 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2153449, encodeId=d1e3215344999, content=偏重的研究方向：肿瘤 经验分享：这个杂志太bug了，我们投稿两个半月，中间显示有5个reviewer accepted，最后居然说没有找到reviewer，就把我们拒了。简直太不负责任了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55d38610766, createdName=Forever066, createdTime=Fri Aug 18 19:19:26 CST 2023, time=2023-08-18, status=1, ipAttribution=广东省)]

2021-12-27 msSSSSSD

什么样的图表可以用来发文章？

37 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=882300, encodeId=b6d4882300bf, content=投稿三天，编辑拒稿，效率还是很高的😂，推荐转投到 biomarker research。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=Dr H, createdTime=Thu Sep 03 00:33:03 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067227, encodeId=ae76106e22758, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实验楼不同方向课题组在一年内试投过5篇，2篇10天内拒稿，2篇送外审一个月后拒稿，1篇大修后接收。请3-4个审稿人，审稿人看的非常细，专业性很强，有创新性要求，article不容易中，基本要所有审稿人都给积极意见才能有机会修回。一般一审10天，送外审的再加3周，从投稿到返回外审意见1个半月。修回再投同样经历送外审差不多一个月返回意见。(状态会经历new submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，revise，revise submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，accept), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dac42363429, createdName=billljc, createdTime=Fri Nov 05 11:52:37 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187268, encodeId=dc64118e268c2, content=这个杂志在华裔主编的运作下从6分涨到20+ 以前文章质量一般配不上十几分但是看了最近半年的国人发的research article 确实还是可以的。个别文章感觉好过cell research😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Sat Jan 22 19:57:20 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103448, encodeId=875d110344881, content=什么样的图表可以用来发文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103447, encodeId=014e110344ed8, content=整理结果过程中，哪张图和哪张图应该放在一起？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579590, encodeId=03805e95904d, content=目前接受一篇。editor assigned完了是reviewers assigned，然后under review，一个月后审完，修改一周后submit，3天后接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/16/effe1e161c052d399c7711bb91050ff8.jpg, createdBy=232e1969427, createdName=1e158756m99(暂无匿称), createdTime=Sat Nov 09 00:00:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589816, encodeId=8d1158981632, content=editor assigned 一周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e9730982, createdName=guoyuanliu, createdTime=Tue Apr 28 00:00:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187866, encodeId=affb218e86669, content=投稿命中率:5.0 经验分享：，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed1e5279534, createdName=1483da0bm95(暂无昵称), createdTime=Sun Feb 18 01:16:58 CST 2024, time=2024-02-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2172085, encodeId=6b8321e2085ce, content=请问接收肺癌靶向治疗方向的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 12:41:53 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2153449, encodeId=d1e3215344999, content=偏重的研究方向：肿瘤 经验分享：这个杂志太bug了，我们投稿两个半月，中间显示有5个reviewer accepted，最后居然说没有找到reviewer，就把我们拒了。简直太不负责任了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55d38610766, createdName=Forever066, createdTime=Fri Aug 18 19:19:26 CST 2023, time=2023-08-18, status=1, ipAttribution=广东省)]

2021-12-27 小动量

整理结果过程中，哪张图和哪张图应该放在一起？

59 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=882300, encodeId=b6d4882300bf, content=投稿三天，编辑拒稿，效率还是很高的😂，推荐转投到 biomarker research。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=Dr H, createdTime=Thu Sep 03 00:33:03 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067227, encodeId=ae76106e22758, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实验楼不同方向课题组在一年内试投过5篇，2篇10天内拒稿，2篇送外审一个月后拒稿，1篇大修后接收。请3-4个审稿人，审稿人看的非常细，专业性很强，有创新性要求，article不容易中，基本要所有审稿人都给积极意见才能有机会修回。一般一审10天，送外审的再加3周，从投稿到返回外审意见1个半月。修回再投同样经历送外审差不多一个月返回意见。(状态会经历new submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，revise，revise submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，accept), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dac42363429, createdName=billljc, createdTime=Fri Nov 05 11:52:37 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187268, encodeId=dc64118e268c2, content=这个杂志在华裔主编的运作下从6分涨到20+ 以前文章质量一般配不上十几分但是看了最近半年的国人发的research article 确实还是可以的。个别文章感觉好过cell research😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Sat Jan 22 19:57:20 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103448, encodeId=875d110344881, content=什么样的图表可以用来发文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103447, encodeId=014e110344ed8, content=整理结果过程中，哪张图和哪张图应该放在一起？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579590, encodeId=03805e95904d, content=目前接受一篇。editor assigned完了是reviewers assigned，然后under review，一个月后审完，修改一周后submit，3天后接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/16/effe1e161c052d399c7711bb91050ff8.jpg, createdBy=232e1969427, createdName=1e158756m99(暂无匿称), createdTime=Sat Nov 09 00:00:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589816, encodeId=8d1158981632, content=editor assigned 一周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e9730982, createdName=guoyuanliu, createdTime=Tue Apr 28 00:00:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187866, encodeId=affb218e86669, content=投稿命中率:5.0 经验分享：，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed1e5279534, createdName=1483da0bm95(暂无昵称), createdTime=Sun Feb 18 01:16:58 CST 2024, time=2024-02-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2172085, encodeId=6b8321e2085ce, content=请问接收肺癌靶向治疗方向的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 12:41:53 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2153449, encodeId=d1e3215344999, content=偏重的研究方向：肿瘤 经验分享：这个杂志太bug了，我们投稿两个半月，中间显示有5个reviewer accepted，最后居然说没有找到reviewer，就把我们拒了。简直太不负责任了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55d38610766, createdName=Forever066, createdTime=Fri Aug 18 19:19:26 CST 2023, time=2023-08-18, status=1, ipAttribution=广东省)]

2019-11-09 1e158756m99(暂无匿称)

目前接受一篇。editor assigned完了是reviewers assigned，然后under review，一个月后审完，修改一周后submit，3天后接受

105 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=882300, encodeId=b6d4882300bf, content=投稿三天，编辑拒稿，效率还是很高的😂，推荐转投到 biomarker research。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=Dr H, createdTime=Thu Sep 03 00:33:03 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067227, encodeId=ae76106e22758, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实验楼不同方向课题组在一年内试投过5篇，2篇10天内拒稿，2篇送外审一个月后拒稿，1篇大修后接收。请3-4个审稿人，审稿人看的非常细，专业性很强，有创新性要求，article不容易中，基本要所有审稿人都给积极意见才能有机会修回。一般一审10天，送外审的再加3周，从投稿到返回外审意见1个半月。修回再投同样经历送外审差不多一个月返回意见。(状态会经历new submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，revise，revise submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，accept), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dac42363429, createdName=billljc, createdTime=Fri Nov 05 11:52:37 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187268, encodeId=dc64118e268c2, content=这个杂志在华裔主编的运作下从6分涨到20+ 以前文章质量一般配不上十几分但是看了最近半年的国人发的research article 确实还是可以的。个别文章感觉好过cell research😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Sat Jan 22 19:57:20 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103448, encodeId=875d110344881, content=什么样的图表可以用来发文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103447, encodeId=014e110344ed8, content=整理结果过程中，哪张图和哪张图应该放在一起？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579590, encodeId=03805e95904d, content=目前接受一篇。editor assigned完了是reviewers assigned，然后under review，一个月后审完，修改一周后submit，3天后接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/16/effe1e161c052d399c7711bb91050ff8.jpg, createdBy=232e1969427, createdName=1e158756m99(暂无匿称), createdTime=Sat Nov 09 00:00:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589816, encodeId=8d1158981632, content=editor assigned 一周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e9730982, createdName=guoyuanliu, createdTime=Tue Apr 28 00:00:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187866, encodeId=affb218e86669, content=投稿命中率:5.0 经验分享：，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed1e5279534, createdName=1483da0bm95(暂无昵称), createdTime=Sun Feb 18 01:16:58 CST 2024, time=2024-02-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2172085, encodeId=6b8321e2085ce, content=请问接收肺癌靶向治疗方向的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 12:41:53 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2153449, encodeId=d1e3215344999, content=偏重的研究方向：肿瘤 经验分享：这个杂志太bug了，我们投稿两个半月，中间显示有5个reviewer accepted，最后居然说没有找到reviewer，就把我们拒了。简直太不负责任了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55d38610766, createdName=Forever066, createdTime=Fri Aug 18 19:19:26 CST 2023, time=2023-08-18, status=1, ipAttribution=广东省)]

2020-04-28 guoyuanliu

editor assigned 一周了

117 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=882300, encodeId=b6d4882300bf, content=投稿三天，编辑拒稿，效率还是很高的😂，推荐转投到 biomarker research。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=Dr H, createdTime=Thu Sep 03 00:33:03 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067227, encodeId=ae76106e22758, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实验楼不同方向课题组在一年内试投过5篇，2篇10天内拒稿，2篇送外审一个月后拒稿，1篇大修后接收。请3-4个审稿人，审稿人看的非常细，专业性很强，有创新性要求，article不容易中，基本要所有审稿人都给积极意见才能有机会修回。一般一审10天，送外审的再加3周，从投稿到返回外审意见1个半月。修回再投同样经历送外审差不多一个月返回意见。(状态会经历new submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，revise，revise submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，accept), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dac42363429, createdName=billljc, createdTime=Fri Nov 05 11:52:37 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187268, encodeId=dc64118e268c2, content=这个杂志在华裔主编的运作下从6分涨到20+ 以前文章质量一般配不上十几分但是看了最近半年的国人发的research article 确实还是可以的。个别文章感觉好过cell research😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Sat Jan 22 19:57:20 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103448, encodeId=875d110344881, content=什么样的图表可以用来发文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103447, encodeId=014e110344ed8, content=整理结果过程中，哪张图和哪张图应该放在一起？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579590, encodeId=03805e95904d, content=目前接受一篇。editor assigned完了是reviewers assigned，然后under review，一个月后审完，修改一周后submit，3天后接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/16/effe1e161c052d399c7711bb91050ff8.jpg, createdBy=232e1969427, createdName=1e158756m99(暂无匿称), createdTime=Sat Nov 09 00:00:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589816, encodeId=8d1158981632, content=editor assigned 一周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e9730982, createdName=guoyuanliu, createdTime=Tue Apr 28 00:00:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187866, encodeId=affb218e86669, content=投稿命中率:5.0 经验分享：，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed1e5279534, createdName=1483da0bm95(暂无昵称), createdTime=Sun Feb 18 01:16:58 CST 2024, time=2024-02-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2172085, encodeId=6b8321e2085ce, content=请问接收肺癌靶向治疗方向的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 12:41:53 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2153449, encodeId=d1e3215344999, content=偏重的研究方向：肿瘤 经验分享：这个杂志太bug了，我们投稿两个半月，中间显示有5个reviewer accepted，最后居然说没有找到reviewer，就把我们拒了。简直太不负责任了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55d38610766, createdName=Forever066, createdTime=Fri Aug 18 19:19:26 CST 2023, time=2023-08-18, status=1, ipAttribution=广东省)]

2024-02-18 1483da0bm95(暂无昵称) 来自河北省

投稿命中率:5.0
经验分享：，

21 0

[GetPortalCommentsPageByObjectIdResponse(id=882300, encodeId=b6d4882300bf, content=投稿三天，编辑拒稿，效率还是很高的😂，推荐转投到 biomarker research。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=Dr H, createdTime=Thu Sep 03 00:33:03 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067227, encodeId=ae76106e22758, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实验楼不同方向课题组在一年内试投过5篇，2篇10天内拒稿，2篇送外审一个月后拒稿，1篇大修后接收。请3-4个审稿人，审稿人看的非常细，专业性很强，有创新性要求，article不容易中，基本要所有审稿人都给积极意见才能有机会修回。一般一审10天，送外审的再加3周，从投稿到返回外审意见1个半月。修回再投同样经历送外审差不多一个月返回意见。(状态会经历new submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，revise，revise submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，accept), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dac42363429, createdName=billljc, createdTime=Fri Nov 05 11:52:37 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187268, encodeId=dc64118e268c2, content=这个杂志在华裔主编的运作下从6分涨到20+ 以前文章质量一般配不上十几分但是看了最近半年的国人发的research article 确实还是可以的。个别文章感觉好过cell research😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Sat Jan 22 19:57:20 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103448, encodeId=875d110344881, content=什么样的图表可以用来发文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103447, encodeId=014e110344ed8, content=整理结果过程中，哪张图和哪张图应该放在一起？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579590, encodeId=03805e95904d, content=目前接受一篇。editor assigned完了是reviewers assigned，然后under review，一个月后审完，修改一周后submit，3天后接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/16/effe1e161c052d399c7711bb91050ff8.jpg, createdBy=232e1969427, createdName=1e158756m99(暂无匿称), createdTime=Sat Nov 09 00:00:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589816, encodeId=8d1158981632, content=editor assigned 一周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e9730982, createdName=guoyuanliu, createdTime=Tue Apr 28 00:00:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187866, encodeId=affb218e86669, content=投稿命中率:5.0 经验分享：，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed1e5279534, createdName=1483da0bm95(暂无昵称), createdTime=Sun Feb 18 01:16:58 CST 2024, time=2024-02-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2172085, encodeId=6b8321e2085ce, content=请问接收肺癌靶向治疗方向的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 12:41:53 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2153449, encodeId=d1e3215344999, content=偏重的研究方向：肿瘤 经验分享：这个杂志太bug了，我们投稿两个半月，中间显示有5个reviewer accepted，最后居然说没有找到reviewer，就把我们拒了。简直太不负责任了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55d38610766, createdName=Forever066, createdTime=Fri Aug 18 19:19:26 CST 2023, time=2023-08-18, status=1, ipAttribution=广东省)]

2023-11-30 周大-Jagger 来自天津

请问接收肺癌靶向治疗方向的文章吗

32 0

[GetPortalCommentsPageByObjectIdResponse(id=882300, encodeId=b6d4882300bf, content=投稿三天，编辑拒稿，效率还是很高的😂，推荐转投到 biomarker research。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=266, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210104/1a4d3d11af7842afadd172a4a59b32f9/66b07e825e8e4455b5099c678c51e0c6.jpg, createdBy=ab332214260, createdName=Dr H, createdTime=Thu Sep 03 00:33:03 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067227, encodeId=ae76106e22758, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：实验楼不同方向课题组在一年内试投过5篇，2篇10天内拒稿，2篇送外审一个月后拒稿，1篇大修后接收。请3-4个审稿人，审稿人看的非常细，专业性很强，有创新性要求，article不容易中，基本要所有审稿人都给积极意见才能有机会修回。一般一审10天，送外审的再加3周，从投稿到返回外审意见1个半月。修回再投同样经历送外审差不多一个月返回意见。(状态会经历new submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，revise，revise submission，editor assigned，reviewer assigned，under review，reviews completed，editor assigned，accept), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=149, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=dac42363429, createdName=billljc, createdTime=Fri Nov 05 11:52:37 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187268, encodeId=dc64118e268c2, content=这个杂志在华裔主编的运作下从6分涨到20+ 以前文章质量一般配不上十几分但是看了最近半年的国人发的research article 确实还是可以的。个别文章感觉好过cell research😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1b72231756, createdName=目标cancer discovery, createdTime=Sat Jan 22 19:57:20 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103448, encodeId=875d110344881, content=什么样的图表可以用来发文章？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1103447, encodeId=014e110344ed8, content=整理结果过程中，哪张图和哪张图应该放在一起？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579590, encodeId=03805e95904d, content=目前接受一篇。editor assigned完了是reviewers assigned，然后under review，一个月后审完，修改一周后submit，3天后接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/16/effe1e161c052d399c7711bb91050ff8.jpg, createdBy=232e1969427, createdName=1e158756m99(暂无匿称), createdTime=Sat Nov 09 00:00:00 CST 2019, time=2019-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589816, encodeId=8d1158981632, content=editor assigned 一周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e9730982, createdName=guoyuanliu, createdTime=Tue Apr 28 00:00:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2187866, encodeId=affb218e86669, content=投稿命中率:5.0 经验分享：，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed1e5279534, createdName=1483da0bm95(暂无昵称), createdTime=Sun Feb 18 01:16:58 CST 2024, time=2024-02-18, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2172085, encodeId=6b8321e2085ce, content=请问接收肺癌靶向治疗方向的文章吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 12:41:53 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2153449, encodeId=d1e3215344999, content=偏重的研究方向：肿瘤 经验分享：这个杂志太bug了，我们投稿两个半月，中间显示有5个reviewer accepted，最后居然说没有找到reviewer，就把我们拒了。简直太不负责任了！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55d38610766, createdName=Forever066, createdTime=Fri Aug 18 19:19:26 CST 2023, time=2023-08-18, status=1, ipAttribution=广东省)]

2023-08-18 Forever066 来自广东省

偏重的研究方向：肿瘤
经验分享：这个杂志太bug了，我们投稿两个半月，中间显示有5个reviewer accepted，最后居然说没有找到reviewer，就把我们拒了。简直太不负责任了！

50 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务